Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaji Hashimoto

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 2, 2005
Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameterKenji Ikeda, Masahiro Kobayashi, Satoshi Saitoh, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|May 11, 2016
Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: relationship with tumor size and cell differentiationArisa Kumagai, Fukuo Kondo, Keiji Sano, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 3, 2018
No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resectionYusuke Kawamura, Kenji Ikeda, Junichi Shindoh, et al.
Liver Cancer|February 20, 2020
<sup>18</sup>F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to LenvatinibYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology|November 7, 2022
Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Liver Cancer|June 19, 2024
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)Akihiko Ichida, Junichi Arita, Etsuro Hatano, et al.
Clinical Journal of Gastroenterology|July 1, 2023
Correction to: Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|September 14, 2022
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based AnalysisNozomu Muraishi, Yusuke Kawamura, Norio Akuta, et al.
Cancers|August 12, 2023
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular CarcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Liver Cancer|July 11, 2020
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall PrognosisYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 2, 2005
Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameterKenji Ikeda, Masahiro Kobayashi, Satoshi Saitoh, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|May 11, 2016
Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: relationship with tumor size and cell differentiationArisa Kumagai, Fukuo Kondo, Keiji Sano, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 3, 2018
No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resectionYusuke Kawamura, Kenji Ikeda, Junichi Shindoh, et al.
Liver Cancer|February 20, 2020
<sup>18</sup>F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to LenvatinibYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology|November 7, 2022
Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Liver Cancer|June 19, 2024
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)Akihiko Ichida, Junichi Arita, Etsuro Hatano, et al.
Clinical Journal of Gastroenterology|July 1, 2023
Correction to: Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|September 14, 2022
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based AnalysisNozomu Muraishi, Yusuke Kawamura, Norio Akuta, et al.
Cancers|August 12, 2023
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular CarcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Liver Cancer|July 11, 2020
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall PrognosisYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Pageof 17